Neuphoria nixes social anxiety program and starts strategic review after phase 3 flop
Neuphoria Therapeutics’ lead candidate has failed to improve social anxiety symptoms in a late-stage trial, prompting the biotech to discontinue the program and launch a strategic review of its business.…